FTXH vs RSPH: Differences, Returns & Fees
Over the year to Nov 18, 2026, FTXH returned +36.1% to RSPH's +29.7%; 27% of their weight is in the same names.
- Return gap
- +6.4 pts1 year to Nov 18, 2026: FTXH ahead, total return
- Fee gap
- 0.20 ptsA year: FTXH 0.60%, RSPH 0.40%, per filings dated Jul 29, 2026 and Aug 27, 2026
- Overlap
- 27%Share of the two books held in common, holdings dated Nov 17, 2026
- Net flow
- −$57m / +$93mFTXH / RSPH, Oct 19, 2026 to Nov 17, 2026, daily basis
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
FTXH +36.1%, RSPH +29.7%: FTXH +6.4 pts ahead, 1 year, Nov 18, 2025 to Nov 18, 2026.
ShareUse this comparison
Client brief:
The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.
Cost to trade
Hypothetical. A $10,000 order in FTXH costs about $7.00 one way and $14.00 in and out, at a median spread of 0.14%. The 0.14% spread is FTXH’s 30-day median, from First Trust (fund page).
Fees over time
Hypothetical. $10,000 in FTXH for 10 years at 0.60% a year costs about $988 in fees and lost growth; RSPH at 0.40% would cost $664. Assumes 6% a year before fees, a sample rate, not a forecast.
Key numbers
RSPH costs 0.20 points a year less; their one-year returns differ by 6.4 points; FTXH is 1.1 times larger.
Pair scorecard
Open the table
| Total return, 1 year | +36.1% | +29.7% |
|---|---|---|
| Below its high | 4.1%, high on Nov 4, 2026 | 4.0%, high on Nov 4, 2026 |
| What it tracks | Nasdaq US Smart Pharmaceuticals Index | S&P 500 Equal Weight Health Care Index |
| Expense ratio | 0.60% | 0.40% |
| Net assets, as of Nov 17, 2026 | $1.1bn | $1.0bn |
| Holdings in common | 27% | |
| Top ten holdings, share of the fund | 56.7% | 19.3% |
The numbers behind it
Net assets on Nov 17, 2026: $1.1bn for First Trust Nasdaq Pharmaceuticals ETF and $1.0bn for Invesco S&P 500 Equal Weight Health Care ETF.
Holdings in common uses holdings dated Nov 17, 2026.
What they share
By the books each fund has filed, FTXH and RSPH hold 27% of their money in the same securities at the same weight. Holdings dated Nov 17, 2026.
half
27% in common
Held in common
Show all 12 holdings
| Eli Lilly and Company | 8.35% | 1.88% |
| Viatris Inc. | 4.23% | 1.86% |
| Biogen Inc. | 3.95% | 1.79% |
| Regeneron Pharmaceuticals, Inc. | 4.09% | 1.77% |
| Gilead Sciences, Inc. | 3.97% | 1.75% |
| Amgen Inc. | 3.63% | 1.75% |
| AbbVie Inc. | 7.79% | 1.75% |
| Zoetis Inc. | 3.69% | 1.72% |
| Johnson & Johnson | 7.15% | 1.57% |
| Pfizer Inc. | 6.82% | 1.56% |
| Vertex Pharmaceuticals Incorporated | 3.35% | 1.54% |
| Illumina, Inc. | 1.60% | 1.49% |
Only in FTXH
Show all 8 holdings
| United Therapeutics Corporation | 3.47% |
| Jazz Pharmaceuticals Plc | 2.61% |
| Exelixis, Inc. | 2.60% |
| Medpace Holdings, Inc. | 1.53% |
| Neurocrine Biosciences, Inc. | 1.34% |
| Halozyme Therapeutics, Inc. | 1.31% |
| Elanco Animal Health Incorporated | 1.26% |
| BioMarin Pharmaceutical Inc. | 1.17% |
Only in RSPH
Show all 8 holdings
| IDEXX Laboratories Inc | 2.02% |
| Mettler-Toledo International Inc | 2.00% |
| GE HealthCare Technologies Inc | 1.88% |
| West Pharmaceutical Services Inc | 1.84% |
| McKesson Corp | 1.84% |
| Edwards Lifesciences Corp | 1.83% |
| Intuitive Surgical Inc | 1.83% |
| Becton Dickinson & Co | 1.80% |
Side by side
Open the table
| Fund | First Trust Nasdaq Pharmaceuticals ETF | Invesco S&P 500 Equal Weight Health Care ETF |
| Where it sits | Stock ETF | Stock ETF |
| Issuer | First Trust | Invesco |
| What it is | Tracks an index | Tracks an index |
| Total return, 1 year | +36.1% | +29.7% |
| Expense ratio | 0.60% | 0.40% |
| Already in the S&P 500 | 73.4% | 100.0% |
| Holdings | 50 | 63 |
| Net assets, as of Nov 17, 2026 | $1.1bn | $1.0bn |
FTXH and RSPH on the fields both publish, as of Nov 18, 2026. Source: ETFIQ.
From Sep 2016 to Nov 2026, RSPH returned more: +180.5% to +154.1%. FTXH and RSPH swung about the same: 18.3% and 18.1%. RSPH fell slightly less at its worst: −27.3% to −28.9%.
Full scorecard
Open the table
| Total return | +154.1% | +180.5% | RSPH | Price change plus distributions, reinvested. |
| Annualized | +9.6% | +10.7% | RSPH | Total return as a yearly rate. |
| Price return | +124.3% | +163.7% | RSPH | Price change alone, distributions left out. |
| Volatility | 18.3% | 18.1% | Tie | Spread of weekly returns, annualized. Lower is steadier. |
| Downside deviation | 12.8% | 12.8% | Tie | Like volatility, counting only weeks below the Treasury bill rate. |
| Max drawdown | −28.9% | −27.3% | RSPH (slight) | Deepest fall from a high to the low after it. |
| Sharpe | 0.46 | 0.51 | RSPH | Return above Treasury bills per unit of volatility. |
| Sortino | 0.65 | 0.73 | RSPH | Return above Treasury bills per unit of downside deviation. |
| Calmar | 0.33 | 0.39 | RSPH | Annualized return divided by the max drawdown. |
More
Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 528 weekly returns. Cash rate: the 13-week Treasury bill.
About FTXH
FTXH tracks an index. Over the year to Nov 18, 2026 it returned +36.1% with distributions reinvested.
More
The prospectus expense ratio is 0.60% a year. By its holdings published by its issuer for Nov 17, 2026, 73% of the fund by weight is stocks the S&P 500 also holds, across 50 positions, with the top ten at 56.7%. It sat 4.1% below its high of Nov 4, 2026 on Nov 18, 2026.
About RSPH
RSPH tracks an index. Over the year to Nov 18, 2026 it returned +29.7% with distributions reinvested.
More
The prospectus expense ratio is 0.40% a year. By its holdings published by its issuer for Nov 17, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 63 positions, with the top ten at 19.3%. It sat 4.0% below its high of Nov 4, 2026 on Nov 18, 2026.
Questions people ask
Which returned more over the last year, FTXH or RSPH?
In the year to Nov 18, 2026, with distributions reinvested, FTXH returned +36.1% and RSPH +29.7%.
Which is cheaper, FTXH or RSPH?
RSPH is cheaper, by 0.20 percentage points a year. That is about $20 on $10,000 held for a year. Fees come from each fund's prospectus.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, FTXH against RSPH, data as of Nov 18, 2026. https://etfiq.com/compare/any/ftxh-vs-rsph
ETFIQ. (Nov 18, 2026). FTXH against RSPH. Retrieved from https://etfiq.com/compare/any/ftxh-vs-rsph
[FTXH against RSPH (ETFIQ, Nov 18, 2026)](https://etfiq.com/compare/any/ftxh-vs-rsph)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.